New serological biomarkers of inflammatory bowel disease
Open Access
- 1 January 2008
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 14 (33), 5115-5124
- https://doi.org/10.3748/wjg.14.5115
Abstract
Serological biomarkers in inflammatory bowel disease (IBD) are a rapidly expanding list of non-invasive tests for objective assessments of disease activity, early diagnosis, prognosis evaluation and surveillance. This review summarizes both old and new biomarkers in IBD, but focuses on the development and characterization of new serological biomarkers (identified since 2007). These include five new anti-glycan antibodies, anti-chitobioside IgA (ACCA), anti-laminaribioside IgG (ALCA), anti-manobioside IgG (AMCA), and antibodies against chemically synthesized (Σ) two major oligomannose epitopes, Man α-1,3 Man α-1,2 Man (ΣMan3) and Man α-1,3 Man α-1,2 Man α-1,2 Man (ΣMan4). These new biomarkers serve as valuable complementary tools to existing biomarkers not only in differentiating Crohn’s disease (CD), ulcerative colitis (UC), normal and other non-IBD gut diseases, but also in predicting disease involvement (ileum vs colon), IBD risk (as subclinical biomarkers), and disease course (risk of complication and surgery). Interestingly, the prevalence of the antiglycan antibodies, including anti-Saccharomyces cerevisiae antibodies (ASCA), ALCA and AMCA, was found to be associated with single nucleotide polymorphisms (SNPs) of IBD susceptible genes such as NOD2/CARD15, NOD1/CARD4, toll-like receptors (TLR) 2 and 4, and β-defensin-1. Furthermore, a gene dosage effect was observed: anti-glycan positivity became more frequent as the number of NOD2/CARD15 SNPS increased. Other new serum/plasma IBD biomarkers reviewed include ubiquitination factor E4A (UBE4A), CXCL16 (a chemokine), resistin, and apolipoprotein A-IV. This review also discusses the most recent studies in IBD biomarker discovery by the application of new technologies such as proteomics, fourier transform near-infrared spectroscopy, and multiplex enzyme-linked immunosorbent assay (ELISA)’s (with an emphasis on cytokine/chemokine profiling). Finally, the prospects of developing more clinically useful novel diagnostic algorithms by incorporating new technologies in serological biomarker profiling and integrating multiple biomarkers with bioinformatics analysis/modeling are also discussed.Keywords
This publication has 83 references indexed in Scilit:
- Applications of proteomics in the study of inflammatory bowel diseasesInflammatory Bowel Diseases, 2009
- Distinct Cytokine Patterns Identified from Multiplex Profiles of Murine DSS and TNBS-Induced ColitisInflammatory Bowel Diseases, 2009
- Interaction between seroreactivity to microbial antigens and genetics in Crohn’s disease: is there a role for defensins?Tissue Antigens, 2008
- Resistin is an inflammatory marker of inflammatory bowel disease in humansEuropean Journal of Gastroenterology & Hepatology, 2007
- New serological markers in inflammatory bowel disease are associated with complicated disease behaviourGut, 2007
- Mutations in pattern recognition receptor genes modulate seroreactivity to microbial antigens in patients with inflammatory bowel diseaseGut, 2007
- Anti-outer membrane of porin C and anti-I2 antibodies in indeterminate colitisGut, 2006
- Genetic basis for increased intestinal permeability in families with Crohn's disease: role of CARD15 3020insC mutation?Gut, 2006
- Serologic Markers in Inflammatory Bowel DiseaseClinical Chemistry, 2006
- Anti- Saccharomyces cerevisiae antibodies in Japanese patients with inflammatory bowel disease: diagnostic accuracy and clinical valueThe Esophagus, 2003